This pilot clinical trial studies the Relaxation Response Resiliency Program in promoting resiliency in lymphoma survivors. The Relaxation Response Resiliency Program may help to reduce stress and stress-related symptoms in lymphoma survivors.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03212261.
PRIMARY OBJECTIVES:
I. To examine the feasibility and acceptability of delivering a group-based stress-management program delivered via videoconference technology for approximately 55 lymphoma survivors who are less than 2 years post-treatment.
SECONDARY OBJECTIVES:
I. Explore the feasibility and acceptability of collecting hair samples to examine intervention-related changes in cortisol, a stress biomarker.
II. Examine the preliminary effects of the intervention on psychosocial measures of fatigue, mindfulness, depressed mood, anxiety, and stress. (exploratory)
OUTLINE:
Participants complete the Relaxation Response Resiliency Program (3RP) via videoconferencing software over 1.5 hours weekly for a total of 8 group sessions.
After completion of study, participants are followed up at 1 month.
Trial PhaseNo phase specified
Trial Typesupportive care
Lead OrganizationDana-Farber Harvard Cancer Center
Principal InvestigatorGiselle Perez
